Pembrolizumab - Redsenol Health

Immunotherapy could help patients with recurrent head and neck cancer live longer

Immunotherapy could help patients with recurrent head and neck cancer live...

redsenol - June 11, 2019

Pembrolizumab plus pemetrexed and carboplatin can improve 24-month overall survival for advanced nonsquamous non–small cell lung cancer

Pembrolizumab plus pemetrexed and carboplatin can improve overall survival for advanced...

redsenol - February 20, 2019

Recent Posts

Redsenol Multi-Peptides: A Breakthrough in Nutritional Science

Cancer Care October 25, 2024

Redsenol Renews Support for Tour de Cure

Cancer Care September 14, 2024

Redsenol Team Presents Ginsenoside Research at the 2023 Canadian Cancer Research Conference

Redsenol Team Presents Ginsenoside Research at the 2023 Canadian Cancer Research...

Cancer Supplement November 16, 2023

Ginsenoside Rg3 Shows Promise in Enhancing Immune Function for Non-Small Cell Lung Cancer Patients

Ginsenoside Rg3 Shows Promise in Enhancing Immune Function for Non-Small Cell...

Ginseng & Ginsenosides October 31, 2023

Ginseng Supplementation Shown to Enhance Health-Related Quality of Life for Patients with Non-Metastatic Breast Cancer Patients

Ginseng Supplementation Shown to Enhance Health-Related Quality of Life for Patients...

Ginseng & Ginsenosides September 28, 2023